Arthur D. Levinson Current Public Company Roles
Arthur D. Levinson is a former CEO and current chairman of Apple, where he has served on the board since 2000 and was elected chairman in 2011, a role he continues to hold as of the latest filings with the SEC and Apple investor relations pages. He also serves on the board of directors at Alphabet, the parent company of Google, where he has been a director since 2009 and participates in governance and compensation committees that influence major capital allocation decisions.
His board tenure at Apple and Alphabet places him among the longest-serving independent directors at two of the largest public companies by market capitalization, with total reported compensation for board service at these companies in the low millions annually, consistent with peer compensation benchmarks for directors of S&P 500 companies as disclosed in proxy statements and annual reports.
Arthur D. Levinson Career Background and Genentech Leadership
Levinson served as CEO of Genentech from 1995 to 2009, during which the company developed multiple blockbuster oncology and immunology drugs and became one of the most valuable biotechnology firms globally, with market capitalization exceeding hundreds of billions at its peak. Under his leadership, Genentech's research pipeline expanded and the company maintained a strong focus on translational science, contributing to approvals for treatments in cancer, autoimmune diseases, and ophthalmology.
After stepping down as CEO, he remained involved at Genentech and later Roche, which acquired Genentech in a landmark transaction completed in 2009, maintaining a full ownership stake in the company. His tenure at Genentech is frequently cited in case studies on biotechnology management and long-term R&D investment strategies, as documented in industry analyses and company histories.
Arthur D. Levinson Education, Honors, and Board Compensation
Levinson holds a Ph.D. in biochemistry from Princeton University and completed postdoctoral research at the University of California, San Diego, building a scientific foundation that informed his later leadership in biotechnology and pharmaceutical companies. His career trajectory from academic research to corporate leadership is often highlighted in profiles of scientists who transitioned to executive roles in the life sciences sector.
His board compensation and total reported pay from Apple and Alphabet are publicly disclosed in annual proxy filings, with recent data showing compensation packages aligned with independent director benchmarks for large-cap companies, including cash retainers and equity awards tied to board service rather than company performance metrics, as detailed in SEC filings and investor presentations available on the companies' official websites.